Head and Neck Cancer Trial Results
HPV Status Can Predict Outcome in Oropharyngeal Cancer
(Posted: 06/19/2009, Updated: 08/09/2010) - Patients with advanced oropharyngeal cancer are more likely to survive if their tumors are HPV positive than if they are HPV negative, according to findings presented at the 2009 ASCO meeting in Orlando.
Cetuximab (Erbitux®) Plus Radiation Beneficial for Patients with Head and Neck Cancer
(Posted: 06/05/2004, Updated: 02/25/2010) - Compared to radiation alone, cetuximab plus radiation therapy improves overall survival of patients with advanced head and neck cancer that has not spread to other parts of the body, according to an article published online November 7, 2009, in Lancet Oncology.
Cetuximab (Erbitux®) Plus Chemo Extends Survival in Advanced Head and Neck Cancer
(Posted: 06/26/2007, Updated: 09/16/2008) - Patients with recurrent or metastatic squamous cell carcinoma of the head and neck who received cetuximab (Erbitux®) in addition to standard chemotherapy lived about three months longer than those receiving chemotherapy alone, according to findings presented at the 2007 ASCO meeting in Chicago.
(Posted: 06/19/2009, Updated: 08/09/2010) - Patients with advanced oropharyngeal cancer are more likely to survive if their tumors are HPV positive than if they are HPV negative, according to findings presented at the 2009 ASCO meeting in Orlando.
Cetuximab (Erbitux®) Plus Radiation Beneficial for Patients with Head and Neck Cancer
(Posted: 06/05/2004, Updated: 02/25/2010) - Compared to radiation alone, cetuximab plus radiation therapy improves overall survival of patients with advanced head and neck cancer that has not spread to other parts of the body, according to an article published online November 7, 2009, in Lancet Oncology.
Cetuximab (Erbitux®) Plus Chemo Extends Survival in Advanced Head and Neck Cancer
(Posted: 06/26/2007, Updated: 09/16/2008) - Patients with recurrent or metastatic squamous cell carcinoma of the head and neck who received cetuximab (Erbitux®) in addition to standard chemotherapy lived about three months longer than those receiving chemotherapy alone, according to findings presented at the 2007 ASCO meeting in Chicago.
